Q2 2026 saw a €115 million out-licensing deal, positive confirmatory trial data, and stable revenues year-over-year, with a 29% H1 product revenue decline. Cash position improved, supporting operations into 2028, and key regulatory milestones are on track.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.